MED10 (mediator complex subunit 10) is a component of the Mediator complex, a coactivator essential for RNA polymerase II-dependent transcription of nearly all protein-coding genes 1. MED10 functions as a scaffold protein that bridges gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery, facilitating preinitiation complex assembly and transcription initiation and elongation 1. Beyond its canonical transcriptional role, MED10 has emerged as an oncogenic driver in multiple cancer types. In hepatocellular carcinoma (HCC), MED10 overexpression correlates with poor clinical outcomes and promotes cell cycle progression, proliferation, and epithelial-mesenchymal transition through RAF1 activation and the MEK/ERK/c-Myc signaling axis 2. MED10 expression also associates with immune cell infiltration patterns in the HCC tumor microenvironment 3. In colorectal cancer progression, MED10 is significantly overexpressed in adenocarcinoma stages and serves as a stage-specific biomarker 4. Similarly, in glioblastoma, MED10 participates in a five-gene prognostic signature predicting patient outcomes and is implicated in regulating cell proliferation and migration 5. MED10 has also been identified in lipid metabolism-related prognostic models for HCC 6 and is upregulated in uterine leiomyoma tissues 7. These findings suggest MED10 warrants investigation as both a therapeutic target and prognostic biomarker across multiple malignancies.